CoChat
Sign Up
Cited by 52Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

CSF tau and β-amyloid as biomarkers for mild cognitive impairment

Open access
Hampel, Harald, Blennow, Kaj·2004·Dialogues in Clinical Neuroscience
DOI 10.31887/dcns.2004.6.4/hhampelPMC PMC3181816
Open this paper in CoChat — free account

Abstract

Early diagnosis of Alzheimer s disease (AD) is relevant in order to initiate symptomatic treatment with antidementia drugs. This will be of greater significance if the drugs aimed at slowing down the degenerative process (secondary prevention) prove to affect AD pathology and are clinically effective, such as γ-secretase inhibitors. However, there is currently no clinical assessment to differentiate the patients with mild cognitive impairment (MCI) who will progress to AD from those with a benign form of memory impairment that is part of the normal aging process. Thus, there is great clinical need for diagnostic and predictive biomarkers, as well as biomarkers for classification purposes, to identify incipient AD in MCI subjects. The most promising cerebrospinal fluid (CSF) biomarker candidates are total tau protein (T-tau), phosphorylated tau protein (P-tau), and the 42-andno acid form offi-amyloid (Aβ42), which may, if used in the right clinical context, prove to have sufficient diagnostic accuracy and predictive power to resolve this diagnostic challenge.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.31887/dcns.2004.6.4/hhampel

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • P-tau showed better specificity for AD compared with T-tau.

    “In a recent study, Hampel's group reported that when compared with T-tau, P-tau showed better specificity for AD (Hampel, and Blennow, 2004).”

    From T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease (2015) · cites this paper as Hampel, and Blennow, 2004

    The “Phosphorylated tau protein” section says P-tau’s specificity for differentiating AD from other dementias seems higher than T-tau’s, and the P-tau181 subsection reports improved specificity for distinguishing AD from LBD. But the paper is a review, and its P-tau181 subsection also reports one comparison in which P-tau181 had 94% specificity versus 100% for T-tau. It therefore does not support an unqualified claim of better specificity across comparisons. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 100

  1. [2]Tomlinson BE. Blessed G. Roth M. Observations on brains of demented old people. J Neurol Sci. 1970 11 205 242 5505685
  2. [3]Fratiglioni L. De Ronchi D. Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999 15 365 375 10600044
  3. [4]Davïes L. Wolska B. Hilbïch C. et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988 38 1688 1693 3054625
  4. [5]DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology and treatment. Lancet Neurol. 2003 2 15 21 12849297
  5. [6]Petersen RC. Smith GE. Waring SC. Ivnik RJ. Tangalos EG. Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 56 303 308 10190820
  6. [7]The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus Report of the Working Group. Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging. 1998 19 109 116 9558143
  7. [8]Frank RA. Galasko D. Hampel H. et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Review. Neurobiol Aging. 2003 24 521 536 12714109
  8. [9]Masters CL. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci U S A. 1985 82 4245 4249 3159021 PMC397973
  9. [10]Haass C. Selkoe DJ. Cellular processing of β-amyloid precursor protein and the genesis of amyloid p-peptide. Cell. 1993 75 1039 1042 8261505
  10. [11]Kang J. ternaire HG. Unterbeck A. et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987 325 733 736 2881207
  11. [12]Vassar R. Bennet BD. Babu-Khan S. et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999 286 735 741 10531052
  12. [13]Wolfe NS. Xia W. Ostaszewski BL. Diehl TS. Kimberly WT. Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 1999 398 513 517 10206644
  13. [14]Yu G. Nïshimura M. Arawaka S. et al. Nicastrin modulates presenilin mediated notch/glp-1 signal transduction and PAPP processing. Nature. 2000 407 48 54 10993067
  14. [15]Francis R. McGrath G. Zhang J. et al. Aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of PAPP, and presenilin protein accumulation. Dev Cell. 2002 3 85 97 12110170
  15. [16]Goutte C. Tsunozaki M. Hale VA. Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A. 2002 99 775 779 PMC117381 11792846
  16. Miller DL. Papayannopoulos IA. Styles J. et al Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease Arch Biochem Biophys. 1993 301 41 52 8442665
  17. [18]Jarrett JT. Berger EP. Lansbury PT. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 32 4693 4697 8490014
  18. [20]Tamaoka A. Kondo T. Odaka A. et al. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid p-protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun. 1994 205 834 842 7999120
  19. [21]Buée L. Bussïere T. Buee-Scherrer V. Delacourte A. Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000 33 95 130 10967355
  20. [22]Vanmechelen E. Vanderstichele H. Davidsson P. et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000 285 49 52 10788705
  21. [23]Ishiguro K. Ohno H. Arai H. et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 1999 270 91 94 10462105
  22. [24]Kohnken R. Buerger K. Zinkowski R. et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000 287 187 190 10863026
  23. [25]Grundke-lqbal I. Iqbal K. Tung YC. Quinland M. Wisniewski HM. Binder LI. Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cytoskeletal pathology Proc Natl Acad Sci U S A. 1986 83 4913 4917 3088567 PMC323854
  24. [26]Iqbal K. Alonso AD. Gondal JA. et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm. 2000 59(suppl) 213 222 10961432
  25. [27]Heine G. Zucht H-D. Schuhmann MU. et al. High-resolution peptide mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central nervous system diseases. J Chromatogr B. 2002 782 353 361 12458018
  26. [28]Van Nostrand WE. Wagner SL. Shankle WR. et al. Decreased levels of soluble amyloid p-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992 89 2551 2555 1557359 PMC48699
  27. [29]Farlow M. Ghetti B. Benson MD. Farrow JS. van Nostrand WE. Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid p-protein precursor in hereditary Alzheimer's disease Lancet. 1992 340 453 454 1354785
  28. [30]Tabaton M. Nunzi MG. Xue R. Usiak M. Autilio-Gambetti L. Gambetti P. Soluble amyloid p-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 200 1598 1603 8185615
  29. [31]van Gool WA. Kuiper MA. Walstra GJ. Wolters EC. Bolhuis PA. Concentrations of amyloid p protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995 37 277 279 7847870
  30. [32]Motter R. Vigo-Pelfrey C. Kholodenko D. et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995 38 643 648 7574461
  31. [34]Vanderstichele H. Blennow K. D'Heuvaert ND. et al. Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinson's Diseases. New York, NY: Plenum Press; 1998 773 778
  32. [36]Blennow K. Hampel H. CSF markers for incipient Alzheimer's disease. Review. Lancet Neurol. 2003 2 605 613 14505582
  33. [37]Strozyk D. Blennow K. White LR. Launer LJ. CSF AP42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003 60 652 656 12601108
  34. [38]Otto M. Esselmann H. Schulz-Shaeffer W. et al. Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 2000 54 1099 1102 10720281
  35. [39]Sjoegren M. Davidsson P. Wallin A. et al. Decreased CSF p-amyloid42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by separate mechanisms. Dem Geriatr Cogn Disord. 2002 13 112 118 11844893
  36. [40]Holmberg B. Johnels B. Blennow K. Rosengren L. Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 2003 18 186 190 12539213
  37. [41]Galasko D. Chang L. Motter R. et al. High cerebrospinal fluid tau and low amyIoid-p-42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998 55 937 945 9678311
  38. [42]Ida N. Hartmann T. Pantel J. et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996 271 22908 22914 8798471
  39. [43]Andreasen N. Minthon L. Vanmechelen E. et al. Cerebrospinal fluid tau and A-p42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett. 1999 273 5 8 10505638
  40. [44]Kanemaru K. Kameda N. Yamanouchi H. Decreased CSF amyloid P42 and normal tau levels in dementia with Lewy bodies. Neurology. 2000 54 1875 1876 10802808
  41. [46]Vanmechelen E. Vanderstichele H. Hulstaert F. et al. Cerebrospinal fluid tau and β-amyloid (1-42) in dementia disorders. Mech Ageing Dev. 2001 122 2005 2011 11589918
  42. [47]Hulstaert F. Blennow K. Ivanoiu A. et al. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF. Neurology. 1999 52 1555 1562 10331678
  43. [48]Sjoegren M. Minthon L. Davidsson P. et al. CSF levels of tau, β-amyloid(142) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 2000 107 563 579 11072752
  44. [49]Maruyama M. Arai H. Sugita M. et al. Cerebrospinal fluid amyloid P(142) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol. 2001 172 433 436 11716567
  45. [50]Hampel H. Teïpel SJ. Fuchsberger T. et al. Value of CSF p-Amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Mol Psychiatry. 2004 9 705 710 14699432
  46. [51]Tamaoka A. Sawamura N. Fukushima T. et al. Amyloid p protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997 148 41 45 9125389
  47. [52]Kanai M. Matsubara E. Isoe K. et al. Longitudinal study of cerebrospinal fluid levels of tau, A-pi-40, and A-pi -42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998 44 17 26 9667589
  48. [53]Shoji M. Matsubara E. Kanai M. et al. Combination assay of CSF Tau, AP1-40, A-pi -42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 1998 158 134 140 9702683
  49. [54]Fukuyama R. Mizuno T. Mori S. Nakajima K. Fushiki S. Yanagisawa K. Age-dependent change in the levels of AP40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to AP40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol. 2000 155 160 10765056
  50. [55]Mehta PD. Pirttilà T. Mehta SP. Sersen EA. Aisen PS. Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid p proteins 1-40 and 1-42 in Alzheimer's disease. Arch Neurol. 2000 57 100 105 10634455
  51. [56]Vigo-Pelfrey C. Lee D. Keim P. Lieberburg I. Schenk DB. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993 61 1965 1968 8229004
  52. [57]Wiltfang J. Esselmann H. Bibl M. et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ-peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroïnflammatïon. J Neuroem. 2002 81 481 496 12065657
  53. [58]Lewczuk P. Esselmann H. Meyer M. et al. The amyloid-p (AP) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ-peptide. Rapid Commun Mass Spectrom. 2003 17 1291 1296 12811752
  54. [59]Vandermeeren M. Mercken M. Vanmechelen E. et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993 61 1828 1834 8228996
  55. [60]Blennow K. Wallin A. Agren H. Spenger C. Siegfried J. Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995 26 231 245 8748926
  56. [61]Vigo-Pelfrey C. Seubert P. Barbour R. et al. Elevation of microtubule associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995 45 788 793 7723971
  57. [62]Jensen M. Basun H. Lannfeldt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 1995 186 189 191 7777193
  58. [63]Riemenschneïder M. Buch K. Schmolke M. Kurz A. Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett. 1996 212 209 211 8843109
  59. [64]Roesler N. Wichart I. Jellinger KA. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996 60 237 238 PMC1073823 8708672
  60. [65]Arai H. Morïkawa Y. Higuchi M. et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997 236 261 264 9240421
  61. [67]Arai H. Terajima M. Miura M. et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995 38 649 652 7574462
  62. [68]Arai H. Higuchi S. Sasaki H. Aβolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology. 1997 43 2 10 9187933
  63. [69]Andreasen N. Vanmechelen E. Van de Voorde A. et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study [see comments]. J Neurol Neurosurg Psychiatry. 1998 64 298 305 9527138 PMC2170016
  64. [70]Kurz A. Riemenschneïder M. Buch K. et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord. 1998 12 372 377 9876968
  65. [71]Nishimura T. Takeda M. Nakamura Y. et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol. 1998 20 227 235 9646285
  66. [72]Tapiola T. Lehtovirta M. Ramberg J. et al. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 1998 50 169 174 9443475
  67. [73]Buerger K. Padberg F. Nolde T. et al. CSF tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease, compared with controls. Neurosci Lett. 1999 277 21 24 10643888
  68. [74]Green AJ. Harvey RJ. Thompson EJ. Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 1999 259 133 135 10025576
  69. [75]Hampel H. Teipel SJ. Padberg F. et al. Discriminant power of combined CSF tau and soluble gp1 30 in the diagnosis of Alzheimer's disease. Brain Res. 1999 823 104 112 10095017
  70. [76]Molina L. Touchon J. Herpé M. et al. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport. 1999 10 3491 3495 10619631
  71. [77]Morikawa Y. Arai H. Matsushita S. et al. Cerebrospinal fluid tau protein levels in demented an nondemented alcoholics. Alcohol Clin Exp Res. 1999 23 575 577 10235290
  72. [78]Kahle PJ. Jakowec M. Teipel SJ. et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 2000 54 1498 1504 10751266
  73. [79]Sjoegren M. Rosengren L. Minthon L. Davidsson P. Blennow K. Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000 54 1960 1964 10822437
  74. [80]Munroe WA. Southwick PC. Chang L. et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 1995 25 207 217 7605102
  75. [81]Galasko D. Clark C. Chang L. et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997 48 632 635 9065538
  76. [82]Mori H. Hosoda K. Matsubara E. et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995 186 181 183 7777192
  77. [83]Blennow K. Vanmechelen E. Hampel H. CSF total tau, A-p42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol. 2001 24 87 97 11831556
  78. [84]Sjoegren M. Davidsson P. Tullberg M. et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001 70 624 630 11309456 PMC1737352
  79. [85]Sjoegren M. Vanderstichele H. Agren H. et al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001 47 1776 1781 11568086
  80. [86]Otto M. Wiltfang J. Tumani H. et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997 225 210 212 9147407
  81. [87]Otto M. Wiltfang J. Cepek L. et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2002 58 192 197 11805244
  82. [88]Kapaki E. Kilidireas K. Paraskevas GP. Michalopoulou M. Patsouris E. Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2001 71 401 403 11511720 PMC1737566
  83. [89]Kudo T. Mima T. Hashimoto R. et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci. 2000 54 199 202 10803815
  84. [90]Hesse C. Rosengren L. Andreasen N. et al. Transient increase in total but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001 297 187 190 11137759
  85. [91]Zemlan FP. Rosenberg WS. Luebbe PA. et al. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem. 1999 72 741 750 9930748
  86. [92]Mitani K. Furiya Y. Uchihara T. et al. Increased CSF tau protein in corticobasal degeneration. J Neurol. 1998 245 44 46 9457628
  87. [93]Urakand K. Mori M. Wada K. et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett. 1999 259 127 129 10025574
  88. [94]Andreasen N. Minthon L. Davidsson P. et al. Evaluation of CSF-tau and CSF-A-p-42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001 58 373 379 11255440
  89. [95]Vanmechelen E. Van Kerschaver E. Blennow K. et al. CSF-Phospho tau (181 P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Disodia S, Winblad B, eds. Alzheimer's Disease: Advances in Etiology Pathogenesis and Therapeutics. Chichester, UK: John Wiley & Sons; 2001
  90. [96]Hu YY. He SS. Wang et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002 160 1269 1278 11943712 PMC1867203
  91. [97]Riemenschneïder M. Wagenpfeïl S. Vanderstichele H. et al. Phosphotau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003 8 343 347 12660807
  92. [98]Buerger K. Zinkowski R. Teipel SJ. et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry. 2003 160 376 379 12562590
  93. [100]Buerger K. Zinkowski R. Teipel SJ. et al. Differential diagnosis of Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Arch Neurol. 2002 59 1267 1272 12164722
  94. [101]Schoenknecht P. Pantel J. Hunt A. et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's diesase. Neurosci Lett. 2003 339 172 174 12614922
  95. [103]Hampel H. Buerger K. Zinkowski R. et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004 61 95 102 14706948
  96. [104]Buerger K. Teipel SJ. Zinkowski R. et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002 59 627 629 12196665
  97. [105]Arai H. Ishiguro K. Ohno H. et al. CSF Phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 2000 166 201 203 11031097
  98. [106]Andreasen N. Vanmechelen E. Vanderstichele H. Davidsson P. Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand. 2003 107 47 51 12603251
  99. [107]Okamura N. Arai H. Maruyama M. et al. Combined analysis of CSF tau levels and [(123)1] iodoamphetandne SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry. 2002 159 474 476 11870015
  100. [108]de Leon MJ. Segal S. Tarshish CY. et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment Neurosci Lett. 2002 333 183 186 12429378

Cited by

Sorted by citations

Authors
Hampel, H., & Blennow, K.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • University of Gothenburg (SE)
Corresponding author
Hampel, Harald
ORCID
Venue
Dialogues in Clinical Neuroscience
Publisher
Informa UK Limited
Published
2004-12-31
Volume
6
Issue
4
Pages
379-390
ISSN
  • 1294-8322 (ISSN-L)
  • 1958-5969
DOI
10.31887/dcns.2004.6.4/hhampel
PMC
PMC3181816
OpenAlex
W4294752670
Cited by
52
References
6
Citations by year
2026: 3 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 5 · 2020: 3 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 1
FWCI
0.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
cerebrospinal fluid biomarkers, mild cognitive impairment, Alzheimer's disease, tau protein, phosphorylated tau, amyloid-beta 42, early diagnosis, diagnostic accuracy, predictive biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review